Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1

Abstract

Members of the ErbB family of receptors have been implicated in regulation of androgen receptor (AR) activity. Ebp1, an ErbB-3 binding protein recently cloned in our laboratory, possesses an LXXLL motif important in mediating interactions with nuclear hormone receptors. Therefore, we sought to determine if Ebp1 could bind AR and influence AR transcriptional activation potential. We demonstrate in this study that Ebp1 bound to AR in vitro and in vivo, and that this binding was increased by androgen treatment. The C terminal 79 amino acids of Ebp1 were sufficient to bind AR. The N terminal domain of AR was responsible for binding Ebp1. Ligand-mediated transcriptional activation of both artificial and natural AR regulated promoters was inhibited by ectopic expression of ebp1 in transient transfection systems. Ebp1 deletion mutants that either lacked the C terminal AR binding region or had a mutated LXXLL motif failed to inhibit AR activated transcription. PSA expression from its endogenous promoter was also decreased in LNCaP prostate cancer cells overexpressing Ebp1. The growth of AR positive LNCaP cells was inhibited by ectopic expression of ebp1, but mutants that failed to repress transcription did not inhibit cell growth. These studies suggest that Ebp1 may play a role in the function of the AR and provide a link between ErbB receptors and the AR.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Aarnisalo P, Palvimo JJ, Janne OA . 1998 Proc. Natl. Acad. Sci. USA 95: 2122–2127

  • Aarnisalo P, Santti H, Poukka H, Palvimo JJ, Janne OA . 1999 Endocrinology 140: 3097–3105

  • Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B . 1999 Mol. Cell. Biol. 19: 6085–6097

  • Bacus SS, Gudkov AV, Zelnick CR, Chin D, Stern R, Stancovski I, Peles E, Ben Baruch N, Farbstein H, Lupu R . 1993 Cancer Res. 53: 5251–5261

  • Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE, Nikiforov M, Haffner R, Gudkov A, Keyomarsi K . 1996 Oncogene 12: 2535–2547

  • Barton J, Blackledge G, Wakeling A . 2001 Urology 58: 114–122

  • Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG . 1999 Mol. Cell. Biol. 19: 8383–8392

  • Craft N, Shostak Y, Carey M, Sawyers CL . 1999 Nat. Med. 5: 280–285

  • Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H . 1994 Cancer Res. 54: 5474–5478

  • Fondell JD, Ge H, Roeder RG . 1996 Proc. Natl. Acad. Sci. USA 93: 8329–8333

  • Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ . 1997 Oncogene 15: 2705–2716

  • Gross M, Liu B, Tan J, French FS, Carey M, Shuai K . 2001 Oncogene 20: 3880–3887

  • Hayes SA, Zannegar M, Sharma M, Yang F, Peehl DM, ten Dijke P, Sun Z . 2001 Cancer Res. 61: 2112–2118

  • He B, Kemppainen JA, Wilson EM . 2000 J. Biol. Chem 275: 22986–22994

  • Heery DM, Kalkhoven E, Hoare S, Parker MG . 1997 Nature 387: 733–736

  • Jenster G . 2000 J. Pathol 191: 227–228

  • Kallioniemi OP, Visakorpi T . 1996 Adv. Cancer Res. 68: 225–255

  • Kemppainen JA, Lane MV, Sar M, Wilson EM . 1992 J. Biol. Chem. 267: 968–974

  • Knudsen KE, Cavenee WK, Arden KC . 1999 Cancer Res. 59: 2297–2301

  • Lessor TJ, Hamburger AW . 2001 Mol. Cell Endocrinol. 175: 185–191

  • Lessor TJ, Yoo JY, Xia X, Woodford N, Hamburger AW . 2000 J. Cell Physiol. 183: 321–329

  • Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP . 2001 J. Biol. Chem. 276: 13442–13451

  • Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng D, Salup R . 1997 Cancer J. Sci. Am. 3: 21–30

  • Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, Harris AL, Horne CH, Neal DE . 1992 J. Urol. 147: 496–499

  • Morote J, de Torres I, Caceres C, Vallejo C, Schwartz S, Reventos J . 1999 Int. J. Cancer 84: 421–425

  • Myers RB, Srivastava S, Oelschlager DK, Grizzle WE . 1994 J. Natl. Cancer Inst. 86: 1140–1145

  • Nagy L, Kao HY, Love JD, Li C, Banayo E, Gooch JT, Krishna V, Chatterjee K, Evans RM, Schwabe JW . 1999 Genes Dev. 13: 3209–3216

  • Perissi V, Staszewski LM, McInerney EM, Kurokawa R, Krones A, Rose DW, Lambert MH, Milburn MV, Glass CK, Rosenfeld MG . 1999 Genes Dev. 13: 3198–3208

  • Petre CE, Wetherill YB, Danielsen M, Knudsen KE . 2002 J. Biol. Chem. 277: 2207–2215

  • Prigent SA, Lemoine NR, Hughes CM, Plowman GD, Selden C, Gullick WJ . 1992 Oncogene 7: 1273–1278

  • Radomski N, Jost E . 1995 Exp. Cell Res. 220: 434–445

  • Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Janne OA, Palvimo JJ, Pestell RG . 2001 Mol. Endocrinol. 15: 797–811

  • Sharma D, Fondell JD . 2000 Mol. Endocrinol. 14: 2001–2009

  • Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M . 2000 J. Natl. Cancer Inst. 92: 1918–1925

  • Slagsvold T, Kraus I, Fronsdal K, Saatcioglu F . 2001 J. Biol. Chem. 276: 31030–31036

  • Stocklin E, Wissler M, Gouilleux F, Groner B . 1996 Nature 383: 726–728

  • Ware JL, Maygarden SJ, Koontz Jr WW, Strom SC . 1991 Hum. Pathol. 22: 254–258

  • Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan D, Hung MC . 2000 Cancer Res. 60: 6841–6845

  • Whitfield GK, Jurutka PW, Haussler CA, Haussler MR . 1999 J. Cell Biochem. Suppl 32–33 110–122

  • Wilson EM, Simental JA, French FS, Sar M . 1991 Ann. NY Acad. Sci. 637: 56–63

  • Xia X, Lessor TJ, Zhang Y, Woodford N, Hamburger AW . 2001a Biochem. Biophys. Res. Commun. 289: 240–244

  • Xia X, Cheng A, Lessor T, Zhang Y, Hamburger AW . 2001b J. Cell Physiol. 187: 209–217

  • Xia X, Serrero G . 1999 Biochem. J. 341: 831–837

  • Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C . 1999 Nat. Med. 5: 280–285

  • Yoo JY, Wang XW, Rishi AK, Lessor T, Xia XM, Gustafson TA, Hamburger AW . 2000 Br. J. Cancer 82: 683–690

  • Zhou YC, Waxman D . 1999 J. Biol. Chem. 274: 29874–29882

Download references

Acknowledgements

This work was supported in part by the Susan Komen Foundation and NIH R01 CA76047 and R21 088882-01 (to AW Hamburger). We thank Dr Olli Janne for the androgen responsive reporter gene and AR expression plasmids, and Dr Martin Gleave for the PSA reporter construct.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anne W Hamburger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, Y., Fondell, J., Wang, Q. et al. Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1. Oncogene 21, 5609–5618 (2002). https://doi.org/10.1038/sj.onc.1205638

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205638

Keywords

This article is cited by

Search

Quick links